3099 Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM). (September 2015) - Gregorc, V.; Gaafar, R.; Favaretto, A.; Grossi, F.; Jassem, J.; Polychronis, A.; Bidoli, P.; Tiseo, M.; O'Brien, M.; Shah, R.; Taylor, P.; Novello, S.; et al.